Endothelial attachment is the initial step in leukocyte recruitment into developing atherosclerotic lesions. To determine whether vascular cell adhesion molecule-i (VCAM-1) expression may play a role in inflammatory cell recruitment into human atherosclerotic lesions, immunohistochemistry was performed with a polyclonal rabbit antisera, raised against recombinant human VCAM-1, on 24 atherosclerotic coronary plaques and 11 control coronary segments with nonatherosclerotic diffuse intimal thickening from 10 patients. Immunophenotyping was performed on adjacent sections to identify smooth muscle cells, macrophages, and endothelial cells. To confirm VCAM-1-expressing cell types, double immunostaining with VCAM-1 antisera and each of the cell-specific markers and in situ hybridization were performed.
Introduction
Gerrity has demonstrated ( 1 ) and Fagiotto and Ross (2, 3) have confirmed that attachment ofmononuclear cells to vascular endothelium is among the first steps in the initiation of atherosclerosis. Vascular cell adhesion molecule-1 (VCAM-1)1 is an inducible molecule that has been shown to mediate endothelial adhesion ofmonocytes and T lymphocytes (4), the principal leukocyte subsets populating atherosclerotic lesions (3) , raising the possibility that VCAM-l may play a role in the recruitment of inflammatory cells into developing atherosclerotic plaques. Evidence supporting this possibility comes from the demonstration of VCAM immunoreactivity on arterial endothelial cells overlying fatty streaks in Watanabe heritable hyperlipidemic rabbits (WHHL) (5) . Although two recent reports have described increased immunoreactivity for intercellular adhesion molecule-1 (ICAM-1) at the arterial luminal surface of atherosclerotic lesions (6, 7) , the presence or location of VCAM-1 has not been demonstrated in human atherosclerotic lesions to date.
The present study was undertaken to determine whether VCAM-1 is expressed in human coronary atherosclerosis by performing immunocytochemical studies on human coronary arteries using a rabbit polyclonal antisera raised against recombinant human VCAM-1. To determine which cell types express VCAM-1 in human atherosclerotic plaques, immunohistochemical studies were performed with monoclonal antibodies to identify smooth muscle cells (SMC) and macrophages, and with the lectin, Ulex europaeus I, to distinguish endothelial cells. In situ hybridization using an antisense riboprobe for VCAM-1 also was performed for further confirmation of VCAM-1 expression.
Methods
Human coronary arterial tissue A total of 35 coronary artery segments obtained from 10 hearts explanted at the time ofcardiac transplantation were placed in methanolCarnoy's solution (60% methanol, 30% chloroform, 10% acetic acid) within 2 h of organ excision, fixed for at least 12 h, and then processed and paraffin-embedded according to conventional techniques. 5 ofthe 10 patients had cardiomyopathy due to atherosclerotic coronary artery disease and the other 5 had idiopathic cardiomyopathy. 6-,Mm sections were used for immunocytochemical analysis. The 35 coronary artery segments were classified according to conventional histologic criteria into (a) atherosclerotic coronary segments, defined by the presence of typical features of luminal narrowing due to regional accumulation of cholesterol, foam cell, and non-foam cell macrophages, and the presence of fibrous caps, or (b) control coronary segments with diffuse intimal thickening consisting of intimal smooth muscle cells and matrix and representing the characteristic morphology of nonatherosclerotic adult human coronary arteries (8) . Additional coronary segments which had been fixed in 10% neutral buffered formalin (NBF) were processed and sectioned in identical fashion and used for in situ hybridization.
Immunohistochemical reagents
Polyclonal VCAM-1 antisera. Polyclonal antisera directed against VCAM-l was generated in rabbits as described previously (9) . Sensitivity and specificity of the VCAM-l antisera were determined by the following criteria: (a) positive immunohistochemical staining by the VCAM-l antisera of VCAM-l-transfected but not of either ICAM-ltransfected or untransfected Chinese hamster ovary (CHO) cells; (b) staining of cells in fixed tissue sections known to express VCAM-1, including dendritic cells in lymphoid follicles ofhuman tonsil and parietal epithelial cells ofhuman kidney; and (c) abolition ofpositive tissue staining on human tonsil and on human coronary atherosclerotic plaques by preincubation of VCAM-l antisera with VCAM-l-transfected CHO cells but not by preincubation ofthe antisera with untransfected or ICAM-l-transfected CHO cells.
Monoclonal antibodies. Immunophenotypic characterization was performed using the following commercially available antibodies: anti-smooth muscle a-actin (10) (Dako Corp., Carpinteria, CA), which in this context is specific for SMC and anti-CD68 (Dako Corp.), which recognizes macrophages (9).
Lectins. Ulex europaeus I, a lectin which binds to the fucose moiety and thereby recognizes endothelial cells, was used as described previously(ll, 12).
Single label immunohistochemistry
Single label immunohistochemistry was performed as described previously (13) , using rabbit VCAM-I antisera at a titer of 1:2,000, and mouse monoclonal antibodies or lectins at the following titers: antismooth muscle a-actin, 1:1,000; anti-CD68, 1:1,000, and Ulex agglutinin, 1:1,000. Briefly, tissue sections were deparaffinized with xylene and then rehydrated with graded alcohols. The slides were blocked with 3% hydrogen peroxide, washed with PBS, incubated for 60 min with the primary antibody or lectin, and then washed again with PBS. A biotin-labeled secondary antibody, either anti-rabbit (for VCAM-1 antisera), anti-mouse (for anti-smooth muscle a-actin or anti-CD 68), or anti-Ulex, then was applied for 30 The VCAM-I polyclonal antisera was adsorbed against transfected CHO cells as described previously (9) . Briefly, cell pellets of -2.5 X I07 cells of VCAM-l-, ICAM-l-, or untransfected cells were collected in PBS and incubated at room temperature for 30 min with the VCAM-I antisera. The suspensions then were centrifuged at 1,200 rpm in a table-top centrifuge and the supernatants collected for incubation on VCAM-l-and ICAM-l-transfected and untransfected CHO cells, as well as on methanol Carnoy's-fixed human tonsil or coronary arteries. Immunohistochemistry then was performed by standard avidinbiotin immunoperoxidase technique as described above, and cell nuclei counterstained with methyl green.
Riboprobe preparation 1 ugofa 1.3-kb fragment ofthe human VCAM-l gene, including 0.4kb of the 3'-untranslated region, in the expression vector pBS (Stratagene Inc., La Jolla, CA) was transcribed into an antisense riboprobe using T3 polymerase, as described previously (13), using 250 JtCi3S-UTP (New England Nuclear, Boston, MA) as the radioactive label. After 60 min incubation at 37°C, the cDNA was digested by adding 1 U RQl DNase (Promega Corp., Madison, WI) and the reaction mixture then was incubated at 37°C for an additional 15 min. Free nucleotides were separated using a Sephadex G-50 (Pharmacia LKB, Uppsala, Sweden) column. A sense riboprobe was also transcribed for control hybridizations from a 1.25-kb fragment of the human VCAM-l gene using T7 polymerase. Probes were stored at -70°C and used within 7 d of synthesis.
In situ hybridization
Arterial tissue sections which had been fixed in NBF and embedded in paraffin were deparaffinized according to standard protocol. In situ hybridization was then performed on adjacent sections using the antisense and sense (control) VCAM-I riboprobes as previously described ( 13) . After the tissue was air dried, it was dipped in NTB2 nuclear emulsion (Kodak) and exposed in the dark at 4°C for 2 wk. Control hybridizations also were performed with the antisense VCAM-l riboprobe on cell pellets of both VCAM-l-transfected and untransfected CHO cells. After developing, sections were counterstained with hematoxylin and eosin.
Results

Immunohistochemistry
All coronary arteries with advanced atherosclerotic lesions demonstrated one or more of three identifiable patterns of VCAM-1 expression in coronary artery segments, namely, VCAM-l expression in association with: (a) arterial luminal endothelial cells, (b) intimal neovasculature, and (c) nonendothelial cells. In most cases this expression was widespread. In contrast, only 45% of control segments contained any VCAM-1 expression, which was sparse, and which was localized to intimal endothelial and nonendothelial cells. Table I (Fig. 1 a) . Staining ofan adjacent section with Ulex agglutinin (Fig. 1 b) identified these VCAM-1 expressing cells as endothelial cells.
Detection of VCAM-J in association with neovasculature and nonendothelial cells. While VCAM-l expression on arterial luminal endothelial cells was equally prevalent in plaques and control segments, the other two staining patterns, that is, VCAM-1 expression in association with intimal neovasculature and in association with nonendothelial cells in the intima, were much more prevalent in plaques than in control segments (Table I) . VCAM-1 expression was present in at least some intimal neovessels in the majority (71%) of plaques. Only one control segment contained any intimal neovasculature and that coronary segment did not have VCAM-l expression. Thus, neovascular VCAM-1 expression was a much more prevalent finding in plaques than was arterial luminal endothelial cell VCAM-1 expression.
The most striking finding of this study was the demonstration ofVCAM-1 expression by nonendothelial cells, which was the most prevalent pattern of VCAM-1 expression in both plaques and control segments. Nonendothelial cell VCAM-1 expression was identified in 92% of plaques but only 18% of control segments (Table I) . Fig. 2 demonstrates these two additional patterns of VCAM-1 expression. Fig. 2 a shows a low power view of the lower intima (top) and upper media (bottom) of a hematoxylin and eosin-stained plaque, with a black arrow identifying the internal elastic lamina. Fig. 2 , b-d, shows higher power views of the central portion of Fig. 2 a, which contains neovascular ingrowth and increased cellularity, with a black arrow identifying the internal elastic lamina. The VCAM-1 antisera (Fig. 2 b) demonstrates that VCAM-I is present in association with the neovasculature. An adjacent section stained with Ulex (Fig. 2 c) confirms the presence of endothelial cells in VCAM-1-positive neovasculature. However, VCAM-1 staining (Fig. 2 b) (Fig. 2 d) . Colocalization studies demonstrated that the majority of VCAM-1 expression in the arterial intima is found in a subset of intimal SMC, but that occasional VCAM-1-positive staining could also be detected on SMC in the upper media (Fig. 2 b) and on subsets of plaque macrophages, including both non-foam cell and foam cell macrophage phenotypes.
Adventitial VCAM-J expression and comparison with neovascular VCAM-J. Because VCAM-l expression has been documented in association with adventitial endothelial cells ( 14) , its presence or absence in adventitial vessels was determined by immunocytochemistry with the VCAM-I antisera in all 35 segments in this study. As shown in Table II , VCAM-1 expression was present in adventitial vessels in the majority of arterial segments with plaques (87.5%), but only in a minority of control coronary segments (27%). The relationship between plaque adventitial and neovascular VCAM-1 expression also was evaluated, as shown in Table III . The majority of plaques had both adventitial and neovascular VCAM-1 expression (62.5%); in only one case was neovascular VCAM-1 expression detected in a plaque without adventitial VCAM-1. However, though VCAM-1 expression was seen in both adventitial vessels and neovasculature in many plaques, adventitial vessel VCAM-1 expression in one region ofthe plaque was not necessarily associated with VCAM-l expression in contiguous neovasculature. Likewise, VCAM-1 expression by neovasculature was not necessarily associated with VCAM-1 expression on underlying adventitial vessels.
Double label immunohistochemistry
To definitively determine which nonendothelial cell types expressed VCAM-1, double label immunohistochemistry was performed with the VCAM-1 antisera and with either antismooth muscle a-actin or anti-CD68 antibodies (Fig. 3) . Cellspecific antibodies were identified with an alkaline phosphatase method and appear red on slides, while the VCAM-l antisera was marked with an immunogold technique and appears black. Double label immunohistochemistry with anti-smooth muscle a-actin and VCAM-l antisera confirmed that VCAM-1 expression by nonendothelial cells in the intima was primarily associated with a subset of intimal SMC (Fig. 3 a) . Positive staining with the VCAM-l antisera could be abolished by preincubation with VCAM-l-expressing CHO cells (Fig. 3 b) .
Occasional intimal macrophages also could be shown to express VCAM-l by double label immunohistochemistry with anti-CD68 and VCAM-l antisera (Fig. 3 c) .
VCAM-l expression by endothelial cells was often quite discrete. Fig. 3 (4) . Because these are the inflammatory cell subsets typically identified in human coronary plaques, it has been proposed that VCAM-1 may play an important role in their recruitment into developing plaques (5, 15) . The present study establishes that cells expressing VCAM-1 are present in advanced human coronary atherosclerosis. The majority of these cells were found in the deeper portions of plaque, in areas of inflammation and neovascularization, as compared to endothelial cells at the arterial lumen. Perhaps the most surprising finding was that although VCAM-I sometimes was found in association with arterial and neovascular endothelial cells, the majority of VCAM-1 expression in plaques occurred in subsets of intimal SMC and macrophages.
Arterial endothelial cell reactivity with the VCAM-1 antisera in human plaques corresponded in appearance to the pattern of VCAM immunoreactivity which has been reported by others in fatty streaks ofWHHL rabbits (5). However, this was an infrequent finding in the present study, possibly because the atherosclerotic segments examined generally contained advanced lesions rather than fatty streaks. Instead, endothelial cell expression ofVCAM-I was most prevalent in areas of neovascularization, usually in association with an adjacent inflammatory cell infiltrate. It has been thought that the majority of inflammatory cells entering the plaque are recruited from the arterial lumen and that plaques go through an orderly development from fatty streak, consisting primarily of macrophages which have accumulated lipid ( 1, 2) , to a fibrofatty lesion, in which smooth muscle cells are recruited from the media to form a "cap" over a core composed of the inflammatory infiltrate and lipid, and finally to a fully developed fibrous lesion, in which the inflammatory core of the lesion has largely resolved (3). According to that hypothesis, further plaque growth may occur in part by infiltration of more macrophages from the arterial lumen and formation of another fibrous cap (3).
This study demonstrates that there is significant expression in the base of plaques ofa molecule that may recruit inflammatory cells. This finding suggests that inflammatory cells may enter the plaque from the vasa vasorum of the arterial media and adventitia. Intimal neovascularization, which occurs by ingrowth of the vasa vasorum into the base of the plaque, thus may provide a further route .for inflammatory cell entry into the base ofthe intima. The stimuli that mediate the ingrowth of the neovasculature present in the base of plaques are not known. In this study, intimal neovascularization was a frequent occurrence, having been identified by histology and confirmed by Ulex staining of endothelial cells in 22/24 of the advanced coronary plaques examined. The expression of VCAM-1 is indicative that the neovascularization process is associated with assumption ofan "activated" state by the endothelial cells ( 16) . This state is likely to be biologically significant, as indicated by the frequent presence of inflammatory cell infiltrate around these neovessels.
VCAM-1 expression by adventitial endothelium also was highly specific for arterial segments involved by plaque, being present in 87.5% of these specimens as compared to 27% of control segments. Also, 15 of 16 (93.8%) plaques with neovascular VCAM-1 expression had adventitial VCAM-1 expression. Thus, expression of VCAM-1 in adventitial vessels and in neovasculature are much more characteristic of plaques than control segments, raising the possibility that factors associated with atherosclerosis may upregulate endothelial cell VCAM-1 expression in both the adventitia and the intima. Several findings suggest that VCAM-1 expression in both adventitia and neovasculature is under local control. First, VCAM-1 was not expressed by every adventitial vessel nor by every neovessel in any specimen examined, so that its expression in plaques did not appear to be constitutive. Second, VCAM-1 expression by adventitial vessels in a particular region of a plaque was not necessarily associated with VCAM-l expression on adjacent neovasculature, consistent with the hypothesis that expression by contiguous adventitial vessels is not a necessary precursor for neovascular VCAM- (14) . Cultured bone marrow-derived fibroblasts recently have been shown by flow cytometry and immunocytochemistry to express VCAM-1 (18) , and TNF-a-stimulated neural cells also express this molecule ( 19) . Recently, expression of VCAM-l on secondary myoblasts during myogenesis has been described (20) Aw.
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Because association of VCAM-l with intimal SMC usually was found in areas of inflammatory cell infiltrate, this suggests that some factors related to inflammation (e.g., release of various cytokines) may control expression ofVCAM-1 by intimal SMC. How VCAM-l expression by SMC in atherosclerotic plaques may promote the process of atherogenesis is unknown.
In the present study, it also was determined that a subset of intimal macrophages expressed VCAM-l as assessed by double immunostaining with VCAM-1 antisera and the anti-macrophage monoclonal antibody, anti-CD68, and as confirmed by in situ hybridization. It is noteworthy that VCAM-l expression recently has been demonstrated in association with macrophages in rheumatoid synovium, but not in synovium from patients with osteoarthritis (21 ) . Thus, specific cytokines that are expressed in the inflammatory state of rheumatoid synovium and induce VCAM-1 expression in macrophages also may regulate its expression by subsets of human coronary intimal macrophages.
Recruitment by VCAM-1 of inflammatory cells into the base ofplaques could have important adverse effects on plaque stability. Macrophages may secrete many proteolytic enzymes, including collagenase and stromelysin, which may weaken the plaque and increase its propensity to rupture (22) . Elegant computer modeling also has been used to demonstrate that the presence ofa soft "load-bearing surface" in the base ofplaques, as could be created by the infiltration ofproteolytic enzyme-releasing inflammatory cells, could increase the mechanical stress on fibrous caps, thereby increasing their propensity to rupture (23) . However, there is not yet sufficient information to conclude that areas ofleukocytic aggregation in atherosclerosis have a greater predilection for rupture than other regions within the plaque.
In summary, the present study demonstrates the presence of VCAM-1 in advanced human coronary atherosclerotic plaques, suggesting a role for VCAM-1 expression in the recruitment ofinflammatory cells into plaques. VCAM-l in association with arterial luminal endothelial cells was infrequent and VCAM-1 in association with neovasculature in the base of plaques more prevalent, suggesting that the intimal neovasculature may be an important site ofcontinued inflammatory cell recruitment into plaques after initiation. VCAM-l expression was demonstrated on SMC in the neointima. Although the functional significance ofthis last finding cannot be assessed as yet, it does suggest that, in addition to mediating inflammatory cell attachment to endothelium, VCAM-1 expression reflects an "activated" state of specific cell types important in atherogenesis. This can be considered analogous to the upregulated expression ofClass II MHC molecules by these SMC in atherosclerosis that has been reported by others ( 16, 24) , and further supports the concept that, at least in part, atherosclerosis is a form of immune injury to the arterial wall.
